Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RD 13

Next Previous
Drug Profile

RD 13

Alternative Names: CD7 CAR-T therapy - Nanjing Bioheng Biotech; CTD-401; RD 13 02; RD-13; RD-13-01; RD13-02 cell infusion

Latest Information Update: 08 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Bioheng Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor T-cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Aplastic anaemia; Haematological malignancies; Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Phase 0 Type 1 diabetes mellitus

Most Recent Events

  • 20 Jul 2025 Phase-0 for Type 1 diabetes mellitus (In children, In infants, In adults, In adolescents) in China (IV) (NCT07142161)
  • 19 Jun 2025 Phase-I clinical trials in Aplastic anaemia (Treatment-experienced) in China (IV) (NCT06622694)
  • 07 Dec 2024 Efficacy data from the phase I trial in Precursor T-cell lymphoblastic leukaemia-lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top